EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

2017-09-04
Price :
Published : Sep-2017
No. of Pages : 50

EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

Summary

Osteoarthritis (OA) is a gradually progressive joint disease that is typically seen in middle-aged to elderly people. According to the American College of Rheumatology (ACR), OA is the most common cause of disability in the elderly. The most commonly affected joints are the knee, hip, hand, and spine. It is characterized by breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining.

To forecast the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the diagnosed prevalent cases (symptomatic) as well as data for the severity segmentation of the diagnosed prevalent cases (symptomatic) from primary market research. In addition, the forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases (symptomatic) of hand OA will increase from 17,948,101 cases in 2016 to 20,413,591 cases in 2026 at an annual growth rate (AGR) of 1.37%, the diagnosed prevalent cases (symptomatic) of knee OA will increase from 15,235,201 cases in 2016 to 17,641,626 cases in 2026 at an AGR of 1.58%, and the diagnosed prevalent cases (symptomatic) of hip OA will increase from 3,361,141 cases in 2016 to 3,867,480 cases in 2026 at an AGR of 1.51%.

Scope

- The Osteoarthritis (OA) EpiCast Report provides an overview of the risk factors and global trends of hand OA, knee OA, and hip OA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- It includes a 10-year epidemiological forecast for the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA segmented by age (beginning at 18 years and older) and sex in these markets. The diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA are further segmented by severity using Kellgren-Lawrence (KL) grading into mild (KL = 2), and moderate to severe (KL = 3 to 4).
- The OA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The OA EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global OA market.
- Quantify patient populations in the global OA market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for OA therapeutics in each of the markets covered.
- Understand magnitude of OA population by disease severity.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Venezuela

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Venezuela Summary Venezuela ranked 187 out of 190 countries in ease of doing business. In July 2017, rating firm Standard & Poor's downgraded Venezuela's economy to CCC with a negative outlook. Moody's also downgraded its rating to Caa3 with a negative outlook, while Fitch rated it at CCC with a negative outlook. Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers. The value of the market was US$12.6 Billion in 2015, having increased from US$5.7 Billion in 2009, at a Compound Annual Growth Rate (CAGR) of 14.1%. Drug prices in Venezuela are ......
$1995

Hepatobiliary Disease Global Clinical Trials Review, H2, 2017

Hepatobiliary Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatobiliary Disease Global Clinical Trials Review, H2, 2017" provides an overview of Hepatobiliary Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatobiliary Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Hemostasis Global Clinical Trials Review, H2, 2017

Hemostasis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemostasis Global Clinical Trials Review, H2, 2017" provides an overview of Hemostasis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemostasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Hemochromatosis Global Clinical Trials Review, H2, 2017

Hemochromatosis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemochromatosis Global Clinical Trials Review, H2, 2017" provides an overview of Hemochromatosis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemochromatosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials databa......
$2500

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017" provides an overview of Hepatic Encephalopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatic Encephalopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma e......
$2500

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Hepatorenal Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatorenal Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500

Hemoglobinopathies Global Clinical Trials Review, H2, 2017

Hemoglobinopathies Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemoglobinopathies Global Clinical Trials Review, H2, 2017" provides an overview of Hemoglobinopathies clinical trials scenario. This report provides top line data relating to the clinical trials on Hemoglobinopathies. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Hepatic Injury Global Clinical Trials Review, H2, 2017

Hepatic Injury Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatic Injury Global Clinical Trials Review, H2, 2017" provides an overview of Hepatic Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatic Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Global Clinical Trials Review, H2, 2017" provides an overview of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.......
$2500